BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 2022:annrheumdis-2021-221425. [PMID: 35338035 DOI: 10.1136/annrheumdis-2021-221425] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Fillatreau S. Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus. Cell Rep Med 2023;4:100903. [PMID: 36652912 DOI: 10.1016/j.xcrm.2022.100903] [Reference Citation Analysis]
2 Bruera S, Chavula T, Madan R, Agarwal SK. Targeting type I interferons in systemic lupus erythematous. Front Pharmacol 2023;13. [DOI: 10.3389/fphar.2022.1046687] [Reference Citation Analysis]
3 Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, Psachoulia K, Erhardt W, Tummala R. Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res 2023;12:e220192. [PMID: 36515083 DOI: 10.2217/cer-2022-0192] [Reference Citation Analysis]
4 Crow MK. Advances in lupus therapeutics: Achieving sustained control of the type I interferon pathway. Curr Opin Pharmacol 2022;67:102291. [PMID: 36183477 DOI: 10.1016/j.coph.2022.102291] [Reference Citation Analysis]
5 Chen H, Huang L, Jiang X, Wang Y, Bian Y, Ma S, Liu X. Establishment and analysis of a disease risk prediction model for the systemic lupus erythematosus with random forest. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1025688] [Reference Citation Analysis]
6 Ceccarelli F, Govoni M, Piga M, Cassone G, Cantatore FP, Olivieri G, Cauli A, Favalli EG, Atzeni F, Gremese E, Iannone F, Caporali R, Sebastiani M, Ferraccioli GF, Lapadula G, Conti F. Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. JCM 2022;11:6016. [DOI: 10.3390/jcm11206016] [Reference Citation Analysis]
7 Moysidou G, T. Boumpas D. Targeted Therapies for Systemic Lupus Erythematosus (SLE): A Critical Appraisal. Systemic Lupus Erythematosus - Pathogenesis and Management [Working Title] 2022. [DOI: 10.5772/intechopen.105811] [Reference Citation Analysis]
8 Gomez A, Parodis I. Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. Autoimmun Rev 2022;21:103188. [PMID: 36089249 DOI: 10.1016/j.autrev.2022.103188] [Reference Citation Analysis]
9 Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Shen M, Duan C, Xie C, Wang H, Li Z, Li B, Wang T. Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus. Front Immunol 2022;13:962393. [DOI: 10.3389/fimmu.2022.962393] [Reference Citation Analysis]
11 Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis. Hum Vaccin Immunother 2022;:2072143. [PMID: 35588699 DOI: 10.1080/21645515.2022.2072143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ganguly D. Therapeutic Targeting of Plasmacytoid Dendritic Cells. Plasmacytoid Dendritic Cells 2022. [DOI: 10.1007/978-981-19-5595-2_9] [Reference Citation Analysis]